SLC5A2 and diabetes mellitus: Among them, sodium-glucose cotransporter type 2 (SGLT-2) and DPP-4 inhibitors are promising drugs for reducing the morbidity of CV diseases related to diabetes, as they have positive data published related to CV outcomes.